Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $168 from $175 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Analyst Reiterates Buy on Gilead as Strong Q1 and Upgraded Yeztugo Outlook Offset EPS Guidance Cut Despite Price Target Reduction to $168
- Gilead Sciences Balances Strong Growth With EPS Hit
- Gilead price target raised to $157 from $155 at Truist
- Closing Bell Movers: Trade Desk, Expedia fall after earnings
- Notable companies reporting after market close